CD8A and neoplasm: While we cannot completely exclude the possibility that HMGCR inhibition may influence other immune cell populations, the observed increase in CD8+ T cell activity suggests that simvastatin primarily promotes tumor cell–specific ferroptotic death without compromising CD8+ T cell function.